{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:39:57Z","timestamp":1785901197197,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Tri-Service General Hospital, National Defense University","award":["TSGH_D_113143, TSGH_D_114136, and TSGH_E_112255"],"award-info":[{"award-number":["TSGH_D_113143, TSGH_D_114136, and TSGH_E_112255"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s15010-025-02695-6","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T08:31:29Z","timestamp":1767429089000},"page":"459-471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of clinical and safety outcomes in patients with Stenotrophomonas maltophilia bacteremia: a trimethoprim\/sulfamethoxazole versus levofloxacin monotherapy"],"prefix":"10.1007","volume":"54","author":[{"given":"Chien-Liang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Yee","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Mei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Kristopher","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Sung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Chung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hsun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"5","key":"2695_CR1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1473-3099(09)70083-0","volume":"9","author":"WJ Looney","year":"2009","unstructured":"Looney WJ, Narita M, M\u00fchlemann K. Stenotrophomonas maltophilia: an emergingopportunist human pathogen. Lancet Infect Dis. 2009;9(5):312\u201323. https:\/\/doi.org\/10.1016\/S1473-3099(09)70083-0.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2695_CR2","doi-asserted-by":"publisher","first-page":"e0003019","DOI":"10.1128\/CMR.00030-19","volume":"34","author":"JS Brooke","year":"2021","unstructured":"Brooke JS. Advances in the microbiology of Stenotrophomonas maltophilia. Clin Microbiol Rev. 2021;34(3):e0003019. https:\/\/doi.org\/10.1128\/CMR.00030-19.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"2695_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jhin.2008.05.020","volume":"70","author":"JI Paez","year":"2008","unstructured":"Paez JI, Costa SF. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect. 2008;70(2):101\u20138. https:\/\/doi.org\/10.1016\/j.jhin.2008.05.020.","journal-title":"J Hosp Infect"},{"issue":"12","key":"2695_CR4","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1086\/340707","volume":"34","author":"E Senol","year":"2002","unstructured":"Senol E, DesJardin J, Stark PC, et al. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis. 2002;34(12):1653\u20136. https:\/\/doi.org\/10.1086\/340707.","journal-title":"Clin Infect Dis"},{"key":"2695_CR5","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3389\/fmicb.2015.00893","volume":"6","author":"YT Chang","year":"2015","unstructured":"Chang YT, Lin CY, Chen YH, et al. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 2015;6:893. https:\/\/doi.org\/10.3389\/fmicb.2015.00893.","journal-title":"Front Microbiol"},{"key":"2695_CR6","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, et al. Infectious diseases society of America 2024 guidance on the treatment of antimicrobial resistant Gram-negative infections. Clin Infect Dis. 2024;ciad403. https:\/\/doi.org\/10.1093\/cid\/ciad403.","DOI":"10.1093\/cid\/ciad403"},{"issue":"6","key":"2695_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.eimce.2022.06.014","volume":"41","author":"V Pintado","year":"2023","unstructured":"Pintado V, Ruiz-Garbajosa P, Aguilera-Alonso D, et al. Executive summary of the consensus document of the Spanish society of infectious diseases and clinical microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria. Enferm Infecc Microbiol Clin (Engl Ed). 2023;41(6):360\u201370. https:\/\/doi.org\/10.1016\/j.eimce.2022.06.014.","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"issue":"6","key":"2695_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/1120009X.2019.1620405","volume":"31","author":"MV An\u0111elkovi\u0107","year":"2019","unstructured":"An\u0111elkovi\u0107 MV, Jankovi\u0107 SM, Kosti\u0107 MJ, et al. Antimicrobial treatment of Stenotrophomonas maltophilia invasive infections: systematic review. J Chemother. 2019;31(6):297\u2013306. https:\/\/doi.org\/10.1080\/1120009X.2019.1620405.","journal-title":"J Chemother"},{"issue":"1","key":"2695_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12941-024-00685-4","volume":"23","author":"N Bostanghadiri","year":"2024","unstructured":"Bostanghadiri N, Sholeh M, Navidifar T, et al. Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2024;23(1):26. https:\/\/doi.org\/10.1186\/s12941-024-00685-4.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"6","key":"2695_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/QCO.0000000000000975","volume":"36","author":"MF Mojica","year":"2023","unstructured":"Mojica MF, Bonomo RA, van Duin D. Treatment approaches for severe Stenotrophomonas maltophilia infections. Curr Opin Infect Dis. 2023;36(6):572\u201384. https:\/\/doi.org\/10.1097\/QCO.0000000000000975.","journal-title":"Curr Opin Infect Dis"},{"issue":"5","key":"2695_CR11","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.cmi.2018.11.008","volume":"25","author":"JH Ko","year":"2019","unstructured":"Ko JH, Kang CI, Cornejo-Ju\u00e1rez P, et al. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis. Clin Microbiol Infect. 2019;25(5):546\u201354. https:\/\/doi.org\/10.1016\/j.cmi.2018.11.008.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"2695_CR12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/antibiotics12050910","volume":"12","author":"AE Maraolo","year":"2023","unstructured":"Maraolo AE, Licciardi F, Gentile I, et al. Stenotrophomonas maltophilia infections: A systematic review and meta-analysis of comparative efficacy of available treatments, with critical assessment of novel therapeutic options. Antibiot (Basel). 2023;12(5):910. https:\/\/doi.org\/10.3390\/antibiotics12050910.","journal-title":"Antibiot (Basel)"},{"issue":"10","key":"2695_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","volume":"137","author":"ND Friedman","year":"2002","unstructured":"Friedman ND, Kaye KS, Stout JE, et al. Health care\u2013associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137(10):791\u20137. https:\/\/doi.org\/10.7326\/0003-4819-137-10-200211190-00007.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2695_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"issue":"5","key":"2695_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","volume":"36","author":"TC Horan","year":"2008","unstructured":"Horan TC, Andrus M, Dudeck MA. CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309\u201332. https:\/\/doi.org\/10.1016\/j.ajic.2008.03.002.","journal-title":"Am J Infect Control"},{"issue":"10","key":"2695_CR16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, et al. Apache II: A severity of disease classification system. Crit Care Med. 1985;13(10):818\u201329. https:\/\/doi.org\/10.1097\/00003246-198510000-00009.","journal-title":"Crit Care Med"},{"issue":"8","key":"2695_CR17","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310. https:\/\/doi.org\/10.1001\/jama.2016.0287.","journal-title":"JAMA"},{"issue":"1","key":"2695_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/ki.2014.328","volume":"87","author":"ME Thomas","year":"2015","unstructured":"Thomas ME, Blaine C, Dawnay A, et al. The definition of acute kidney injury and its use in practice. Kidney Int. 2015;87(1):62\u201373. https:\/\/doi.org\/10.1038\/ki.2014.328.","journal-title":"Kidney Int"},{"key":"2695_CR19","unstructured":"Sanford JP. The Sanford guide to antimicrobial therapy. Antimicrobial Therapy, Inc; 2007."},{"issue":"8","key":"2695_CR20","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.3390\/jcm13082275","volume":"13","author":"WS Nwkidy","year":"2024","unstructured":"Nwkidy WS, Zaman KA, Abidi E, et al. Clinical outcomes of Trimethoprim\/Sulfamethoxazole in critically ill patients with Stenotrophomonas maltophilia bacteremia and pneumonia utilizing renal replacement therapies. J Clin Med. 2024;13(8):2275. https:\/\/doi.org\/10.3390\/jcm13082275.","journal-title":"J Clin Med"},{"issue":"6","key":"2695_CR21","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1093\/jac\/dkaf131","volume":"80","author":"WP Chen","year":"2025","unstructured":"Chen WP, Chen CL, Siu LK, et al. Antibiotic treatment of Stenotrophomonas maltophilia bacteraemia: does trimethoprim\/sulfamethoxazole dose affect clinical outcomes? J Antimicrob Chemother. 2025;80(6):1716\u201325. https:\/\/doi.org\/10.1093\/jac\/dkaf131.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2695_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","volume":"15","author":"NC Chesnaye","year":"2021","unstructured":"Chesnaye NC, Stel VS, Tripepi G, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2021;15(1):14\u201320. https:\/\/doi.org\/10.1093\/ckj\/sfab158.","journal-title":"Clin Kidney J"},{"issue":"28","key":"2695_CR23","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379. https:\/\/doi.org\/10.1002\/sim.6607.","journal-title":"Stat Med"},{"issue":"1","key":"2695_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1128\/AAC.01682-13","volume":"58","author":"SY Cho","year":"2014","unstructured":"Cho SY, Kang CI, Kim J, et al. Can Levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother. 2014;58(1):581\u20133. https:\/\/doi.org\/10.1128\/AAC.01682-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"2695_CR25","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.2147\/IDR.S416678","volume":"16","author":"P Boonmee","year":"2023","unstructured":"Boonmee P, Nasomsong W, Lorchirachoonkul N, et al. The activities of antimicrobials against Stenotrophomonas maltophilia isolates and evaluation of clinical outcomes among treatment regimens in patients with Stenotrophomonas maltophilia infections: A retrospective multicenter cohort study. Infect Drug Resist. 2023;16:5173\u201384. https:\/\/doi.org\/10.2147\/IDR.S416678.","journal-title":"Infect Drug Resist"},{"issue":"1","key":"2695_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1128\/AAC.01324-13","volume":"58","author":"YL Wang","year":"2014","unstructured":"Wang YL, Scipione MR, Dubrovskaya Y, et al. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 2014;58(1):176\u201382. https:\/\/doi.org\/10.1128\/AAC.01324-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"2695_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jgar.2017.09.015","volume":"12","author":"L Watson","year":"2018","unstructured":"Watson L, Esterly J, Jensen AO, et al. Sulfamethoxazole\/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections. J Glob Antimicrob Resist. 2018;12:104\u20136. https:\/\/doi.org\/10.1016\/j.jgar.2017.09.015.","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"2695_CR28","doi-asserted-by":"publisher","first-page":"ofab644","DOI":"10.1093\/ofid\/ofab644","volume":"9","author":"SH Sarzynski","year":"2022","unstructured":"Sarzynski SH, Warner S, Sun J, et al. Trimethoprim-sulfamethoxazole versus Levofloxacin for Stenotrophomonas maltophilia infections: A retrospective comparative effectiveness study of electronic health records from 154 US hospitals. Open Forum Infect Dis. 2022;9(2):ofab644. https:\/\/doi.org\/10.1093\/ofid\/ofab644.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"2695_CR29","doi-asserted-by":"publisher","first-page":"e00788","DOI":"10.1128\/AAC.00788-19","volume":"63","author":"C Nys","year":"2019","unstructured":"Nys C, Cherabuddi K, Venugopalan V, et al. Clinical and microbiologic outcomes in patients with monomicrobial Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 2019;63(11):e00788\u201319. https:\/\/doi.org\/10.1128\/AAC.00788-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"2695_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jgar.2024.05.016","volume":"38","author":"TA Almangour","year":"2024","unstructured":"Almangour TA, Alkherb Z, Alruwaite S, et al. Trimethoprim-sulfamethoxazole versus Levofloxacin for the treatment of Stenotrophomonas maltophilia infections: A multicentre cohort study. J Glob Antimicrob Resist. 2024;38:42\u20138. https:\/\/doi.org\/10.1016\/j.jgar.2024.05.016.","journal-title":"J Glob Antimicrob Resist"},{"key":"2695_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.puhe.2022.10.025","volume":"214","author":"HJ Appaneal","year":"2023","unstructured":"Appaneal HJ, Lopes VV, LaPlante KL, et al. Treatment, clinical outcomes, and predictors of mortality among a National cohort of hospitalized patients with Stenotrophomonas maltophilia infection. Public Health. 2023;214:73\u201380. https:\/\/doi.org\/10.1016\/j.puhe.2022.10.025.","journal-title":"Public Health"},{"issue":"2","key":"2695_CR32","doi-asserted-by":"publisher","first-page":"106367","DOI":"10.1016\/j.ijantimicag.2021.106367","volume":"58","author":"SJ Junco","year":"2021","unstructured":"Junco SJ, Bowman MC, Turner RB. Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim\/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy. Int J Antimicrob Agents. 2021;58(2):106367. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106367.","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"2695_CR33","doi-asserted-by":"publisher","first-page":"e18916","DOI":"10.7759\/cureus.18916","volume":"13","author":"T Tuncel","year":"2021","unstructured":"Tuncel T, Akal\u0131n H, Sr., Payasl\u0131o\u011flu M, et al. Healthcare-associated Stenotrophomonas maltophilia bacteraemia: retrospective evaluation of treatment and outcome. Cureus. 2021;13(10):e18916. https:\/\/doi.org\/10.7759\/cureus.18916.","journal-title":"Cureus"},{"issue":"1","key":"2695_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/AAC.00133-06","volume":"52","author":"S Kiem","year":"2008","unstructured":"Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother. 2008;52(1):24\u201336. https:\/\/doi.org\/10.1128\/AAC.00133-06.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2695_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1365-2885.2010.01228.x","volume":"34","author":"L Winther","year":"2011","unstructured":"Winther L, Guardabassi L, Baptiste KE, et al. Antimicrobial disposition in pulmonary epithelial lining fluid of horses. Part I. Sulfadiazine and Trimethoprim. J Vet Pharmacol Ther. 2011;34(3):277\u201384. https:\/\/doi.org\/10.1111\/j.1365-2885.2010.01228.x.","journal-title":"J Vet Pharmacol Ther"},{"issue":"1","key":"2695_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhin.2004.01.033","volume":"57","author":"E Senol","year":"2004","unstructured":"Senol E. Stenotrophomonas maltophilia: the significance and role as a nosocomial pathogen. J Hosp Infect. 2004;57(1):1\u20137. https:\/\/doi.org\/10.1016\/j.jhin.2004.01.033.","journal-title":"J Hosp Infect"},{"issue":"11","key":"2695_CR37","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s10096-023-04648-z","volume":"42","author":"V Terlizzi","year":"2023","unstructured":"Terlizzi V, Tomaselli M, Giacomini G, et al. Stenotrophomonas maltophilia in people with cystic fibrosis: a systematic review of prevalence, risk factors and management. Eur J Clin Microbiol Infect Dis. 2023;42(11):1285\u201396. https:\/\/doi.org\/10.1007\/s10096-023-04648-z.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"2695_CR38","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1128\/AAC.40.12.2859","volume":"40","author":"MW Garrison","year":"1996","unstructured":"Garrison MW, Anderson DE, Campbell DM, et al. Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother. 1996;40(12):2859\u201364. https:\/\/doi.org\/10.1128\/AAC.40.12.2859.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2695_CR39","doi-asserted-by":"publisher","first-page":"e00301","DOI":"10.1128\/AAC.00301-18","volume":"62","author":"MB Sanchez","year":"2018","unstructured":"Sanchez MB, Martinez JL. Overexpression of the efflux pumps SmeVWX and SmeDEF is a major cause of resistance to Co-trimoxazole in Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2018;62(6):e00301\u201318. https:\/\/doi.org\/10.1128\/AAC.00301-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2695_CR40","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3390\/antibiotics11121788","volume":"11","author":"A Prawang","year":"2022","unstructured":"Prawang A, Chanjamlong N, Rungwara W, et al. Combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia infections: A systematic review and Meta-Analysis. Antibiot (Basel). 2022;11(12):1788. https:\/\/doi.org\/10.3390\/antibiotics11121788.","journal-title":"Antibiot (Basel)"},{"issue":"4","key":"2695_CR41","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/archinte.163.4.402","volume":"163","author":"PA Masters","year":"2003","unstructured":"Masters PA, O\u2019Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med. 2003;163(4):402\u201310. https:\/\/doi.org\/10.1001\/archinte.163.4.402.","journal-title":"Arch Intern Med"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02695-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02695-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02695-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:39:46Z","timestamp":1770021586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02695-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2695"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02695-6","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board and Ethics Committee associated with Tri-Service General Hospital of National Defense Medical Center (Approval No 2-101-05-074). The requirement for informed consent from each patient was waived because the study design was retrospective and anonymized patient and hospital data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}